VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therape ...

A once-daily oral tablet, sparsentan is fully approved to reduce proteinuria in patients ages 8 and older with FSGS who do ...

Lupus nephritis has a high burden of kidney and non-kidney damage accrual due to persistent disease activity, treatment-related toxicity, and age-related factors.

High blood sugar can complicate symptoms of Peyronie’s disease, and getting it under control may help you see improvements.

This is a developing news story. Please check back soon for updates. The FDA granted full approval to sparsentan for ...

David Novak and his late wife Wendy — who died from Type 1 diabetes complications in 2024 — spent their lives advocating for ...

Researchers at Toronto's Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that ...

The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity ...

GLP-1 medications may not always work for weight loss. New research suggests that around 10% of people carry genetic ...